S. Ng

发表

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.

P. Mitchell, C. Begley, T. Kilpatrick, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Obesity and breast disease. The role of the female sex hormones

D. Ingram, S. Ng, A. Roberts, 1989, Cancer.

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

F. Saad, C. Drake, C. Logothetis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabazitaxel in patients with metastatic castration‐resistant prostate cancer: safety and quality of life data from the Australian early access program

A. Guminski, H. Gurney, P. Parente, 2017, Asia-Pacific journal of clinical oncology.

Clinical perspectives: Practical insights from clinical experience with cabazitaxel in Australia

H. Gurney, P. Parente, M. Bahre, 2015, Asia-Pacific journal of clinical oncology.

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

M. Stockler, C. Gedye, I. Davis, 2020 .

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

P. Kantoff, F. Saad, C. Parker, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing Management and Survival in Patients With Stage IV Colorectal Cancer

N. Tebbutt, C. Platell, S. Ng, 2011, Diseases of the colon and rectum.

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

P. Albers, J. Gschwend, G. Di Lorenzo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

J. Zalcberg, I. Davis, J. Cebon, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Abiraterone in metastatic prostate cancer without previous chemotherapy.

F. Saad, E. Basch, J. Carles, 2013, The New England journal of medicine.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

N. Agarwal, C. Drake, H. Scher, 2014, The Lancet. Oncology.

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

N. Agarwal, C. Drake, H. Scher, 2020, European urology.

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

K. Pittman, L. Klotz, R. Coleman, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

M. Stockler, A. Scott, C. Gedye, 2021, The Lancet.

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

K. Pittman, L. Klotz, R. Coleman, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

R. Huddart, E. Gallardo, N. Agarwal, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).

J. Machiels, J. Picus, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, J. Bono, 2012 .

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen

J. Carles, H. Pandha, J. Bono, 2012 .

1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

N. Lawrentschuk, B. Tran, I. Davis, 2022, Annals of Oncology.

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502).

N. Lawrentschuk, I. Davis, P. Grimison, 2020 .

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

V. Gebski, D. Goldstein, J. Zalcberg, 2016, Cancer Chemotherapy and Pharmacology.

Plasma cetuximab concentrations correlate with survival in patients with advanced KRAS wild type colorectal cancer

D. Tu, L. Siu, M. Jeffery, 2023, Clinical Colorectal Cancer.

High-dose methotrexate for primary CNS lymphoma in the elderly.

M. Rosenthal, D. Ashley, L. Cher, 2000, Neuro-oncology.

Quality of life in patients with K‐RAS wild‐type colorectal cancer

D. Tu, M. Moore, H. Au, 2014, Cancer.

PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

J. Carles, J. Bono, V. Matveev, 2013 .

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

P. Albers, J. Gschwend, G. Di Lorenzo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.